ONCT Projected Dividend Yield
Oncternal Therapeutics Inc ( NASDAQ : ONCT )Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology therapies for the treatment of cancers with critical unmet medical need. Co.'s two clinical-stage product candidates are zilovertamab and ONCT-216. Co. is developing ONCT-216, an investigational small molecule that inhibits the ETS, or E26 Transformation Specific, family of oncoproteins, which have been shown in preclinical studies to alter gene transcription and RNA processing and lead to increased cell proliferation and invasion. In addition, Co. is developing ONCT-808, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. 20 YEAR PERFORMANCE RESULTS |
ONCT Dividend History Detail ONCT Dividend News ONCT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |